A Phase I/II Study of Weekly Topotecan and Gefitinib in Patients With Platinum-Resistant Ovarian, Peritoneal, of Fallopian Tube Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 30 Oct 2017
At a glance
- Drugs Topotecan (Primary) ; Gefitinib
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 25 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2019.
- 22 Oct 2015 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017 as reported by ClinicalTrials.gov.
- 22 Oct 2014 Planned End Date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov record.